JP Morgan Chase
NDRM

JP Morgan Chase’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

JP Morgan Chase’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-739,334
Closed -$28.8M – 5768
2017
Q3 		$28.8M Buy
739,334
+738,742
+124,788% +$27.2M 0.01% 1256
2017
Q2 		$18K Hold
592
– – ﹤0.01% 4561
2017
Q1 		$16K Buy
+592
New +$14.7K ﹤0.01% 4746

Other funds holding NDRM

VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return

JP Morgan Chase's NDRM Position: Q4 2017 in Review

JP Morgan Chase sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q4 2017, closing a stake of 739,334 shares — an estimated $28.8M sold.

JP Morgan Chase first reported a position in NDRM in Q1 2017 and held it in 3 quarters. The position peaked at $28.8M in Q3 2017. 5 funds tracked by Wall St. Rank hold NDRM as of Q4 2017.

  • JP Morgan Chase reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • JP Morgan Chase sold 739,334 NeuroDerm Ltd. Ordinary Shares shares in Q4 2017, an estimated $28.8M.
  • JP Morgan Chase first reported a position in NeuroDerm Ltd. Ordinary Shares in Q1 2017 and held it in 3 quarters.
  • JP Morgan Chase's NeuroDerm Ltd. Ordinary Shares position peaked at $28.8M in Q3 2017.
  • 5 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q4 2017.

Based on JP Morgan Chase's 13F filing for Q4 2017, filed 13 Feb 2018.